NASDAQ · XBIOW
Xenetic Biosciences, Inc.
Healthcare · Biotechnology
$17.54
Down-$5.40 (-23.54%)
Updated Sep 25, 2026, 10:37 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.62M
- P/E ratio
- -1.19
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 2
- Avg. volume
- 635
Price performance
XBIOW price history
1M range · 0 trading sessions · Daily adjusted prices
XBIOW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest XBIOW news
The latest Smart Investors Daily articles mentioning XBIOW.
Stock researchCompany · Overview
XBIOW research
Overview
Company profile and research snapshot.
Company profile
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
